Equities Analysts Issue Forecasts for CRSP FY2025 Earnings

Key Points

• Cantor Fitzgerald has revised down its FY2025 earnings per share (EPS) estimate for CRISPR Therapeutics to ($7.33), compared to the previous estimate of ($6.71) and the consensus estimate of ($5.16).
• CRISPR Therapeutics reported an EPS of ($1.29) for the previous quarter, which surpassed the consensus estimate of ($1.47), while quarterly revenue was significantly below expectations at $0.89 million against a consensus of $6.44 million.
• The company's stock ratings show mixed signals, with recent reports including a "buy" rating from HC Wainwright and a "sell" rating from Wall Street Zen, indicating a diverse analyst outlook on the stock's performance.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Wednesday, August 6th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($7.33) per share for the year, down from their previous estimate of ($6.71). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Cantor Fitzgerald also issued estimates for CRISPR Therapeutics' FY2026 earnings at ($6.71) EPS.

A number of other equities analysts have also issued reports on CRSP. Needham & Company LLC restated a "buy" rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. JMP Securities restated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Bank of America reduced their target price on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. The Goldman Sachs Group reduced their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Finally, Barclays lifted their price objective on CRISPR Therapeutics from $42.00 to $56.00 and gave the company an "equal weight" rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $71.60.

CRISPR Therapeutics Stock Performance

CRSP stock traded down $0.96 during midday trading on Friday, reaching $55.00. The stock had a trading volume of 1,602,286 shares, compared to its average volume of 3,641,424. The stock has a market cap of $5.00 billion, a PE ratio of -10.13 and a beta of 1.80. The firm has a fifty day simple moving average of $51.60 and a two-hundred day simple moving average of $43.92. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. The company had revenue of $0.89 million during the quarter, compared to analyst estimates of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%. The firm's quarterly revenue was up 72.5% on a year-over-year basis. During the same quarter last year, the business posted ($1.49) EPS.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director Simeon George bought 989,812 shares of the company's stock in a transaction dated Wednesday, July 16th. The shares were purchased at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the transaction, the director directly owned 1,730,179 shares of the company's stock, valued at approximately $90,021,213.37. The trade was a 133.69% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider owned 6,068 shares in the company, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors have recently modified their holdings of the business. ARK Investment Management LLC grew its position in shares of CRISPR Therapeutics by 13.3% during the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock valued at $345,929,000 after acquiring an additional 1,192,336 shares during the period. Baker BROS. Advisors LP grew its position in shares of CRISPR Therapeutics by 55.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after acquiring an additional 464,936 shares during the period. Vanguard Group Inc. boosted its holdings in CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock worth $68,329,000 after buying an additional 10,579 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management acquired a new stake in CRISPR Therapeutics in the 1st quarter worth about $416,000. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in CRISPR Therapeutics by 14.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock worth $1,334,000 after buying an additional 4,914 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.